Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

"Cardiomyopathy" is an umbrella term for diseases of the heart muscle that negatively impact its structure and ...

BACKGROUND: The ability to predict recovery of left ventricular ejection fraction (LVEF) in response to guideline-directed therapy among patients with nonischemic cardiomyopathy is desired. We sought ...

Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...

Drawing inferences from observational data with possible confounding Heart failure is increasing in prevalence and is a major cause of morbidity and mortality worldwide,1 with prevalence ranging from ...

Systolic congestive heart failure is when the left side of the heart weakens, and the heart can't pump effectively. It can cause a variety of symptoms.

Background: Standard pharmacotherapy for patients with heart failure with reduced ejection fraction (HFrEF) comprises “quadruple therapy” with a renin–angiotensin system inhibitor, a β-blocker, a ...

Therapies are needed for patients with heart failure with mildly reduced or preserved ejection fraction. New research findings on the nonsteroidal mineralocorticoid receptor antagonist finerenone ...

TX45 is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, offering potential therapeutic benefits for hypertension and heart failure with preserved ejection fraction (HFpEF). Tectonic ...

Metabolomic profiling of 61 metabolites was performed in 527 participants from DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients With HF With Reduced Ejection ...

Study Rundown: Mineralocorticoid receptor antagonists (MRAs) reduce hospitalizations and mortality in patients with heart failure with reduced ejection fraction (HFrEF). However, their effect in those ...